Latest / Cell & Gene: The Podcast

Scaling CRISPR for Rare Disease with Aurora Therapeutics' Dr. Edward Kaye
We love to hear from our listeners. Send us a message.
On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases. Aurora is initially targeting phenylketonuria (PKU) using a platform approach that leverages shared components, such as lipid nanoparticles and base editors, while customizing guide RNAs for specific mutations. Dr. Kaye explains how trials, regulatory flexibility, and optimized manufacturing could make it possible to treat…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.